AIM Research
    Back to Reports
    Market Report

    Agentic AI Use Cases in Life Sciences

    October 3, 2025
    ▮
    Subscribers-only report— contact us to request subscriber access.Request Access

    Subscribers-only report

    This report is available to subscribers. Contact us to request access.

    Request Subscriber Access

    Agentic AI refers to autonomous AI systems capable of making decisions, executing complex workflows, and adapting to changing environments with minimal human intervention. Unlike traditional AI, Agentic AI combines reasoning, planning, and execution to automate processes and generate actionable insights, making it particularly suited to the data-intensive and highly regulated nature of the life sciences industry.

    Across the pharmaceutical value chain, Agentic AI is being adopted in drug discovery, clinical trials, pharmacovigilance, regulatory affairs, manufacturing, and supply chain management to accelerate research, improve operational efficiency, support compliance, and enhance decision-making. Emerging applications such as biomarker discovery, disease modeling, diagnostics, and multimodal patient data integration are also advancing precision medicine and personalized therapies.

    As adoption expands, Agentic AI is enabling life sciences organizations to streamline research and operations, accelerate innovation, and improve patient outcomes, positioning it as a key technology for next-generation pharmaceutical and healthcare transformation.

    Frequently asked questions

    The PeMa (Penetration and Maturity) Quadrant is AIM Research's 2x2 vendor evaluation framework. It measures each provider's market penetration (clients, deal sizes, geographic spread) and technology maturity (capabilities, platforms, partnerships), and places them as Leaders, Seasoned Vendors, Growth Vendors or Challengers.

    Any enterprise technology vendor active in the relevant market category can request to participate. AIM Research issues an open RFI for each study and invites qualifying vendors via the Research Calendar.

    Vendors are evaluated through a structured RFI process backed by primary research, including vendor briefings, customer references and product evaluations. They are scored across 40+ weighted criteria covering product capabilities, strategy and market impact, and the weighted scores are mapped to one of the four quadrant positions.

    The date of the next edition has not been announced yet. Upcoming studies and their RFI windows are listed on the AIM Research Calendar.